Montalban X, et al. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. PR2086. EAN 2017.
RAS-ALS: Effectiviteit van rasagiline in subgroepen
mrt 2024 | Bewegingsstoornissen